Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783576 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10GAATSHR | |
| SCHEMBL11128475 | 0.77 | GAA (0.44) | ALDH1A1LMNAHSD17B10GAATSHR | |
| SCHEMBL784015 | 0.77 | ALDH1A1 (0.35) | ALDH1A1LMNAHSD17B10GAATDP1 | |
| SCHEMBL9625829 | 0.77 | GAA (0.44) | ALDH1A1LMNAHSD17B10GAATSHR | |
| SCHEMBL28436042 | 0.77 | THRB (0.44) | ALDH1A1LMNAHSD17B10GAATSHR | |
| SCHEMBL7896884 | 0.76 | GAA (0.46) | ALDH1A1LMNAHSD17B10GAATSHR | |
| SCHEMBL10441557 | 0.75 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10GAATSHR | |
| SCHEMBL783994 | 0.73 | ALDH1A1 (0.48) | ALDH1A1LMNAGAATSHRMGAM | |
| SCHEMBL783630 | 0.73 | HDAC4 (0.33) | HSD17B10 | |
| SCHEMBL3336021 | 0.73 | GAA (0.41) | ALDH1A1LMNAHSD17B10GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104788485-B | The method for preparing antiviral agent | 百时美－施贵宝爱尔兰控股公司 | 2017-10-03 | — | — | CN | disclosed |
| CN-104788485-A | Process for preparing antiviral agent | BRISTOL MYERS SQUIBB CO | 2015-07-22 | — | — | CN | disclosed |
| CN-102675355-B | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| CN-102412416-A | Nonaqueous electrolyte and nonaqueous electrolyte battery | SONY CORP | 2012-04-11 | — | — | CN | disclosed |
| US-20120070730-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS ELECTROLYTE BATTERY | SONY CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070730-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS ELECTROLYTE BATTERY | SONY CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2005053609-A2 | METHODS OF NAD+-DEPENDENT DEACETYLASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20040254372-A1 | Compounds, derivatives, compositions, preparation and uses | EISAI INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2003014121-A9 | COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES | GUILFORD PHARM INC (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003014121-A1 | COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254372-A1 | Compounds, derivatives, compositions, preparation and uses | PARP1, PARP2, PARP3 | ALDH1A1 1746/4885LMNA 55/4885HSD17B10 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.